Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2019 Earnings Conference Call - Final Transcript
May 13, 2019 • 04:30 pm ET
Welcome to Capricor Therapeutics First Quarter 2019 Conference Call. My name is Chris, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session; and instructions will follow at that time. (Operator Instructions) As a reminder, this call will be recorded.
I would now like to introduced your -- I would now like to turn the call over to Capricor CFO, AJ Bergmann. Please go ahead.
Thank you, and good afternoon.
Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. These statements may include statements regarding among other things the efficacy, safety and intended utilization of our product candidates, our future research and development plans including our anticipated conduct and timing of preclinical and clinical studies, our plans to present or report additional data, our plans regarding regulatory filings, potential regulatory developments involving our product candidates and our possible uses of existing cash and investment resources.
These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the SEC, including our quarterly and annual reports. You're cautioned not to place undue reliance on these forward-looking statements, and we disclaim any obligation to update such statements.
With that, I will turn the call over to Linda Marban, CEO.
Good afternoon, and thank you for joining us for our first quarter update and conference call. Although this call will be brief, the first quarter had been a busy one, as we continue to gather data and prepare for the interim analysis on the HOPE-2 clinical trial. We along with the DMD community eagerly await the data from the interim analysis of HOPE-2, while in the background, we are continuing the development of our exosome platform technology. I'm pleased to provide you with an update on both programs today.
We are actively working with our statisticians, steering committee and the rest of our teams to plan the types of data analysis, we would like for the HOPE-2 interim analysis. As I mentioned in our call last quarter, we believe that the data from approximately 20 patients, who have had more than one dose of cells will help inform us of the best path forward in terms of trial design and adjudication for HOPE-2. We are on track to be able to share the results of the interim analysis during the early part of the third quarter of 2019.
Without going into too much detail, we will of course, be looking carefully at the targeted primary efficacy endpoint, the performance of the upper limb measure both 1.2 and 2.0, but also at many of the other secondary and exploratory endpoints to evaluate the impact of CAP-1002 on the pathogenesis of Duchenne